For questions, please call 616-234-5569 or email
CHCC@vai.org
.
Lymphoma describes a heterogenous group of lymphoid malignancies involving different lymphocyte subsets in different stages of differentiation. Spontaneous lymphoma in the dog mimics Non-Hodgkin's Lymphoma (NHL) in humans, sharing similar biologic, behavioral, cytogenetic and clinical characteristics. Though it does not rank among the most common cancer types, NHL is not infrequent in humans and has an age-adjusted incidence of 10 - 25/100,000 depending on race and gender (SEER statistics). However, it is the most common hematopoeitic cancer in dogs, with an estimated annual incidence of 30/100,000 and thus is easily recruited for clinical studies.
To study NHL, the Canine Hereditary Cancer Consortium (CHCC) has assembled a team under the direction of Dr. Nicola Mason 
at the University of Pennsylvania. In this project, we aim to utilize dogs with spontaneous lymphoma to identify therapeutically relevant tumor antigens and molecular pathways that represent bona fide targets for adjunct immunotherapy of NHL.
